1999
DOI: 10.1038/sj.jhh.1000815
|View full text |Cite
|
Sign up to set email alerts
|

Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women

Abstract: Co-administration of antihypertensive drug therapy and hormonal replacement therapy (HRT) is frequent in postmenopausal women but it is not known whether HRT interacts with concomitant antihypertensive therapy. The present study was designed to investigate efficacy and safety of the ACE inhibitor moexipril in comparison to placebo in hypertensive, postmenopausal women on HRT.After a 4-week placebo run-in phase, 95 postmenopausal women (35-74 years of age) who had a sitting diastolic blood pressure (BP) of 95-1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2002
2002
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 28 publications
0
4
0
Order By: Relevance
“…In placebo‐controlled multicenter trials in Europe and the United States of an 8‐ to 12‐week duration in patients with mild to moderate essential hypertension (SDBP 95–114 mmHg), moexipril was more effective than placebo. Given in single daily doses of 7.5 to 30 mg, moexipril produced sustained blood pressure control over 24 hours and decreased the SDBP from 4 to 11 mmHg over placebo, 21,22,48,49 with a response rate of 48% to 61% for those receiving moexipril 7.5 and 15 mg/d versus 29% and 34% for those receiving placebo, respectively 22 …”
Section: Clinical Experience With Moexipril In Hypertensionmentioning
confidence: 99%
“…In placebo‐controlled multicenter trials in Europe and the United States of an 8‐ to 12‐week duration in patients with mild to moderate essential hypertension (SDBP 95–114 mmHg), moexipril was more effective than placebo. Given in single daily doses of 7.5 to 30 mg, moexipril produced sustained blood pressure control over 24 hours and decreased the SDBP from 4 to 11 mmHg over placebo, 21,22,48,49 with a response rate of 48% to 61% for those receiving moexipril 7.5 and 15 mg/d versus 29% and 34% for those receiving placebo, respectively 22 …”
Section: Clinical Experience With Moexipril In Hypertensionmentioning
confidence: 99%
“…The studies included participants from a wide range of medical conditions including hypertension, transient ischemic attack, coronary artery disease, proteinuria, heart failure, and organ transplant. The basic characteristics of the studies are in Table 1 15–149 . A total of 44 RCT compared ACEI with placebo, 68 RCT with ARB, and 35 RCT with CCB.…”
Section: Resultsmentioning
confidence: 99%
“…The selection of a specific antihypertensive drug in these patients should be grounded on the results of trials specifically aimed at hypertension in the older woman, taking into consideration aspects of safety and tolerability. There is increasing evidence that ACE inhibitors seem to be the medications of first choice in this population, not just because they are effective, but also because they do not cause further deterioration in the parameters of the menopausal metabolic syndrome, and since they may act in synergy with estrogen replacement therapy [31,49].…”
Section: Discussionmentioning
confidence: 99%
“…After 12 weeks of treatment, an adequate antihypertensive response was documented in hypertensive postmenopausal women, without interference with hormonal treatment [49].…”
Section: The Current Pharmacologic Approachmentioning
confidence: 99%